In the Johns Hopkins study, participants and therapists were told that patients would
receive psilocybin on both occasions and that the dose could vary.
The researchers randomly assigned the participants to
receive psilocybin in either their first or second testing session.
They all received both psilocybin and an amphetamine - like compound (Ritalin), which has some psychoactive effects, such as increasing heart rate and increasing concentration.
Volunteers reported mildly altered states of consciousness after
receiving psilocybin but noted no adverse physiological effects.
Volunteers reported feeling less depressed and anxious two weeks after
receiving psilocybin but not two weeks after niacin alone.
The patients knew they were
receiving psilocybin (an «open - label» trial) and the effect of psilocybin was not compared with a placebo.
Not exact matches
The volunteers
received one dose of
psilocybin or the vitamin niacin.
When not given
psilocybin, the subjects
received methylphenidate, more commonly known as Ritalin, which shares some of the pharmacological effects of its psychedelic counterpart.
In the second study, at New York University (NYU) in New York City, 29 cancer patients randomly
received either
psilocybin or niacin, a compound that mimics some side effects of
psilocybin — including a flushed, hot feeling — but without the hallucinogenic properties.
For the study, 20 treatment resistant depression patients
received a 10 mg dose of the
psilocybin and a second 25 mg dose a week later.